The vast majority of rare diseases (RDs) are complex, disabling, and life-threatening conditions with a genetic origin. RD patients face significant health challenges and limited treatments, yet the extent of their impact within health care is not well known. One direct method to gauge the disease burden of RDs is their overall cost and utilization within health-care systems.
The 2016 Healthcare Cost and Utilization Project (HCUP) databases were used to extract health-care utilization data using International Classification of Diseases, Tenth Revision (ICD-10) codes.
Of 35.6 million national hospital weighted discharges in the HCUP Nationwide Inpatient Sample, 32% corresponded to RD-associated ICD-10 codes. Total charges were nearly equal between RDs ($768 billion) compared to common conditions (CCs) ($880 billion) (p < 0.0001). These charges were a result of higher charges per discharge and longer length of stay (LOS) for RD patients compared to those with CCs (p < 0.0001). Health-care cost and utilization was similarly higher for RDs with pediatric inpatient stays, readmissions, and emergency visits.
Pediatric and adult discharges with RDs show substantially higher health-care utilization compared to discharges with CCs diagnoses, accounting for nearly half of the US national bill.
Rare diseases (RDs) are a global health-care problem with an estimated 400 to 700 million people affected worldwide [1,2,3]. Currently, the number of RDs has been suggested to be more than 10,000 ; these diseases are often serious, quality of life-limiting, and potentially life-threatening. Most RDs have some level of genetic involvement, with 72–80% of these conditions having an identified gene or genes [5, 6]. In the United States, RDs are defined as any condition affecting fewer than 200,000 individuals, which collectively affects an estimated 33 million people . In Europe, the European Medicines Agency (EMA) specifies a prevalence of less than 5 in 10,000 people (~75 million), and in Japan the Ministry of Health, Labour and Welfare defines RDs as any condition affecting less than 50,000 individuals in the country (~12.5 million) .
Patients living with RDs experience significant health, psychosocial, occupational, and financial burden. The financial burden of RDs includes both direct (medical and nonmedical) and indirect costs. Direct medical or health-care cost burden can reach millions of dollars annually for certain rare diseases, with cost drivers that include hospitalizations and emergency visits, medications, dental health, palliative care, outpatient visits, insurance cost and reimbursement, rehabilitation care, home health care, assistive devices, social services, and caregivers [9,10,11,12,13,14,15]. RD patients typically experience significant diagnostic delay averaging over 5 years [16, 17], and requires the involvement of a knowledgeable and comprehensive clinical care team to determine a definitive diagnosis.
The overall health-care utilization by pediatric and adult populations with RDs in the United States has not been well documented. Evidence is emerging that RDs may have a disproportionate and substantial impact within health care that well exceeds RD patient prevalence. A recent study analyzed health-care utilization of pediatric patients with 919 genetic diseases and found a marked increase in those patients with one or more genetic diseases . Aggregate total charges for suspected genetic diseases, many of which are rare, in 2012 accounted for ~$57 billion (46%) of the “national bill” for pediatric patients . However, pediatric patient inpatient stays account for only a small component of the total impact of rare disease in health care, and a current and broad inquiry of RDs is necessary.
The present study is a comprehensive investigation of health-care utilization of adult and pediatric patients with RDs compared to those without a RD in the United States. These data span all inpatient, readmission, and emergency department data within the same year (2016) using the Healthcare Cost and Utilization Project (HCUP) database. Here we report the widespread economic impact of RDs in the United States across all demographics. This amplifies the need to incorporate cost-saving measures and improved health-care access for those affected by rare disease.
MATERIALS AND METHODS
The 2016 Nationwide Inpatient Sample (NIS), Kids’ Inpatient Database (KID), Nationwide Readmissions Database (NRD), and Nationwide Emergency Department Sample (NEDS) HCUP data were used to extract health-care utilization and cost data for 1,645 International Classification of Diseases, Tenth Revision (ICD-10) codes linked to RDs. The ICD-10 code list linked to 1,645 RDs, or features of them, was primarily provided by Orphanet , a worldwide database dedicated to providing information on rare diseases and orphan drugs , and does not include ICD-10 codes for all rare diseases. Common conditions (CCs) were defined as any condition not included in the RD ICD-10 list. Of the 1,645 ICD-10 codes and linked RDs, 1,091 have some level of genetic involvement (66.3%) as determined using OMIM and Orphanet [19, 21]. The 2016 HCUP database was selected because, at the time of analysis, it is the most recent set of data that includes the KID database, which is released every 4 years.
The NIS database is the largest publicly available all-payer inpatient health-care database designed to produce US national estimates of inpatient utilization, access, charges, and outcomes. For the year 2016, NIS contains an administrative and demographic data sample that includes an estimated 97% of discharges in the United States from hospitals in 46 states and the District of Columbia , from which a random 20% sample is derived. An estimated 35.6 million hospital weighted discharges were identified in the 2016 NIS HCUP database, of which 11 million correspond to the 1,645 ICD-10 codes from suspected RD diagnoses of record (32%) and 24 million correspond to CC discharges (31%) (Table 1). The types and locations of hospitals from which the NIS data were derived are described in Table S1.
The HCUP-KID database contains an all-payer, national sample of pediatric inpatient discharges for patients younger than 21 years of age . The KID database includes conditions and treatments that are normally difficult to treat, including rare disease and uncommon treatments (e.g., organ transplants), allowing for health-care utilization to be thoroughly investigated . In the year 2016, a total of 6 million weighted discharges were identified for children less than 21 years of age in the 2016 KID HCUP database, of which 1 million (21%) correspond to RDs versus 5 million to CCs (79%).
The HCUP NRD is drawn from 27 HCUP State Inpatient Databases (SID) and can be used to create estimates of 30-day, all-cause hospital readmissions rates and their associated costs . Overall, there were 16 million readmissions in the year 2016, of which 5 million correspond to patients with RDs (32%) and 11 million (68%) to CCs patients.
The NEDS database is drawn from the SID and State Emergency Department Databases (SEDD) . For the year 2016, 36 states and the District of Columbia contributed to the database, representing 78% of all US emergency department visits. In 2016, there were approximately 178 million ED visits in the United States, of which 14 million (10%) correspond to patients with RDs and 130 million (90%) to patients with CCs. All n’s in each database are estimates and analysis of each data element may vary due to missing values.
Clinical and nonclinical hospitalization data elements were extracted from the HCUP NIS, KID, NRD and NEDS databases for selected ICD-10 codes linked to RDs diagnosis. Sample nonclinical data elements included (1) demographic information (sex, age, race, median household income, patient location), (2) primary payer, (3) hospital characteristics (location and region), and (4) total charges. Sample clinical related information included (1) primary diagnosis, (2) discharge status, (3) origin and disposition of the patient, (4) type of admission, (5) hospital discharges, and (6) length of stay (LOS). The following additional data elements were extracted from the KID database: (1) neonatal age and (2) uncomplicated vs. complicated in-hospital birth; from the NRD database: (1) transfer to rehabilitation, evaluation, or other aftercare; and from the NEDS database: (1) total number of ED visits. The number of discharges was provided from total discharges and the n was not further provided for each data element, which varied for each data element due to missing content. The description of each HCUP data element is included in table S2.
A retrospective analysis of 2016 HCUP NIS, KID, NEDS, and NRD was conducted. The estimated prevalence data was adjusted for the US population using the discharge weight variable (DISCWT) to minimize the margin of error and to reflect all 50 states across the United States. To establish the impact of rare disease, patients in the RD cohort were included if they had a suspected rare disease diagnosis from the list of 1,645 ICD-10 codes within the first 15 diagnoses. Descriptive statistics of the weighted national estimates were used to summarize the results. Continuous variables are presented as means and standard error of the mean (SEM). Categorical variables were shown in percentage values. Two-sided tests (chi-square and Fisher’s exact for categorical measures, and Student’s t tests for continuous measures) were used for RD and CC comparisons. Data presented in Tables 1–4 used separate chi-square tests and there were no multiple comparisons. All statistical tests used in this paper were two-tailed. Statistical significance was considered for p < 0.05. All analyses and appropriate weighted estimates were calculated using SAS (version 9.4; SAS Institute Inc., Cary, NC).
The study followed the required research practices based on the Agency for Healthcare Research and Quality (AHRQ)’s recommendations including (1) identifying observations as hospitalization events rather than unique patients, (2) not performing state-level or physician-level analyses, (3) not using nonspecific secondary diagnosis codes to infer in-hospital events, (4) using survey-specific analysis methods allowing for weighting of estimates to generate national estimates with an accompanying measure of variance of the estimate, and (5) not including data from any condition with ten or fewer encounters.
To better understand the economic impact and health-care utilization of RD, a comprehensive analysis of inpatient, readmission, and emergency visits in 2016 was conducted. A RD in a patient’s record was the single biggest predictor of health-care services, and included duration, type, and cost of that utilization when comparing to CCs. These factors were analyzed in detail to provide a comprehensive assessment of the impact of RD in health care. The individual conditions included in the study, as well as average age, LOS, and total charges are included in Table S3.
Health-care utilization was captured using total aggregate inpatient charges, LOS, and charges per inpatient visit. Hospital inpatient visits reflect the single largest cost source in health care, and therefore, provide the most significant component of RD health-care utilization. Overall, total aggregate charges were $768 billion for RDs and $880 billion CCs in the 2016 NIS HCUP database, a remarkable difference of nearly $111 billion (Fig. 1a; p < 0.0001) despite RD patients accounting for a very small percentage of the overall US population [1,2,3].
The present study shows significant differences in health-care utilization between RD and CC discharges. RDs had a longer LOS (6.3 days) compared to CCs (3.8 days) (Fig. 1b; p < 0.0001), and nearly double the average total charges per discharge ($69,275 ± 1004) compared to CCs ($36,718 ± 389) (Fig. 1c; p < 0.0001).
Pediatrics are of great interest for rare disease. Despite representing only 20.9% of total inpatient stays for children less than 21 years of age, total aggregate charges were approximately $34 billion higher for RDs ($105 billion) than CCs ($70 billion) (Fig. 1a; p < 0.0001). The mean total charge per patient was $89,618 ± 289 for RDs and $14,226 ± 23 for CCs (Fig. 1c, p < 0.0001). The mean LOS was over three times longer for RDs (9.1 days) compared to CCs (2.8 days) (Fig. 1b; p < 0.0001).
RDs also had a disproportionate impact on readmission and emergency visits. Data from the NRD showed that patients with RDs had a lower readmission rate (32%) but higher total charges per readmission than patients with CCs ($66,675 ± 98 vs. $35,585 ± 28, p < 0.0001) (Fig. 1c). The impact of RDs was much lower in the emergency department (ED), accounting for 9.7% of overall ED visits. The total charges per visit were greater for RDs ($4,670 ± 108) than CCs ($3,397 ± 76, p < 0.0001) (Fig. 1c), resulting in $55 billion for RDs compared to $384 billion for CCs (Fig. 1a; p < 0.0001).
In addition to total charges and LOS, the overall impact of RD is more fully understood by the number of procedures per inpatient stay, patients’ transfer among facilities, and mortality rate. In the NIS database, RD patients have more inpatient procedures, with 9.1% having 6–15 procedures compared to 3.5% for CCs. Furthermore, fewer RD patients were routinely discharged (e.g., home) (56.4%) compared to CC patients (75.0%). Instead, RD patients were frequently transferred to another facility (22.7%) or required home health care (16.0%). Unfortunately, four times as many RD patients died (3.9%) during their inpatient stay compared to CC (1.0%) patients (p < 0.0001) (Table 1).
In the pediatric population, RD patients had fewer routine discharges (88.1%) compared to CC patients (96.4%) (p < 0.0001), and more RD patients were transferred to another facility or home health care (5.7%) compared to CC discharges (1.9%). Mortality rates were 13 times higher in RDs (1.3%) compared with CCs (0.1%) (p < 0.0001; Table 2), with mortality remaining significantly higher across all age groups. One of the most striking differences between RD and CC was specific to a subset of patients at birth. When determining those patients who were born within the admitting hospital to those newborns who were transferred from another acute care hospital or health-care facility, RD patients were found to have taken a very different pathway. Approximately 58% of RD patients were transferred from another hospital or care facility compared to only 36% of CC patients. Of those born in the same hospital, 94% of RD births were complicated (e.g., cesarean section, birth trauma) compared to 55% of CC patients. Upon further evaluation of this striking difference of birth complications revealed racial disparity. Normal births were similar in breakdown by race between RD and CC patients.
For ED visits, only 56.3% of RD patients were treated and released, and 51.1% were admitted to the same hospital. In contrast, most of the CC visits were treated and released (89.1%) with only 9.0% admitted to the hospital (p < 0.0001). Moreover, 12 times more RD patients (2.3%) died in the ED or later as an inpatient in the hospital, compared with those with CCs (0.2%) (Table 4).
Given the large number of discharges, it was important to better understand the patient population within the sample. Overall, the frequency of RDs in males was 7.9% higher than in CCs in the NIS database. Surprisingly, the average age was higher with RD, 58.3 years, compared to 44.7 years for CCs. There was also a difference in race, with White patients more frequently diagnosed with a RD (68.2%) than CC (64.1%), and fewer Hispanic RD patients (9.8%) compared to CC (13.4%). Private insurers were the primary payer for CCs (33.0%) while public payers, Medicare and Medicaid, were the primary payer for RD visits (70.6%) (Table 1).
Children admitted with a RD were on average 4.7 years old, whereas children with a CC averaged 3.9 years old (p < 0.0001). Most patients were White for both RD (47.3%) and CCs (51.6%). For both RDs and CC, the primary payer was Medicaid. However, when RDs were further evaluated by race, a much higher percentage of White RD patients used private insurance (54.4%) compared to Black (22.0%) and Hispanic (22.8%) patients (Table S4). The NIS, KID, NRD, and NEDS demographic data are further described in Tables 1–4.
There is a clear and immediate public health interest relating to the socioeconomic impact and management of RDs to develop sustainable health policy measures. Systematic quantification of the economic burden of RDs at the national level will help illuminate the direct financial consequences of rare conditions in the health system. We captured various types of health-care utilization HCUP data, the largest all-payer databases of discharges in the United States, to estimate the economic burden of patients suffering from RDs by analyzing the inpatient, readmission, and ED cost burden within health care. Overall, discharges with RD-associated codes show disproportionately higher health-care cost and utilization across all age groups compared with discharges with CC diagnoses.
Rare diseases have a massive impact in US health care
People with RDs disproportionately utilized health-care systems, particularly with inpatient stays where RD patients had more discharges and readmissions, longer LOS, and greater charges per inpatient stay. Here, we report that for the year 2016, overall national total charges were similar for RDs compared to all other CCs. Moreover, pediatric charges were $34 billion greater for RDs than CCs. Limited reports of the disproportionate cost burden of RD have emerged in recent years. In Hong Kong, inpatient health care of 467 RDs was shown to account for 4.3%, or HKD 1,594,339,530 ($204,402,504), of overall inpatient costs in 2015–2016 . Likewise, a systematic literature review of the cost of illness studies assessed the indirect and direct cost of ten rare conditions in the European Union in the year 2010 . Annual direct cost for patients with RDs ranged from €3,858 ($4,334) for scleroderma to €23,066 ($25,911) for hystiocytosis . While these studies analyze far fewer conditions compared to the current study with limited scope, as well as report on non-US health-care systems, the health-care utilization and financial impact is still large and suggests issues that expand well beyond the United States.
The cost of RD highlights significant concern around payer utilization. With the average cost per patient and total cost for RDs being incredibly high, payers and best practices for delivering quality health care may influence patient outcomes and long-term national spending. In the current study we report that overall, RDs accounted for an estimated $768 billion in inpatient costs alone in 2016, with each inpatient stay averaging $69,275. Following the initial inpatient stay, these costs may increase significantly, with increased rates of readmission and transfer to expensive care options (e.g., discharge to home health care or another facility). As a result, the demands placed on RD patients and their families to manage the cost burden are daunting, particularly when 70.6% require a public payer (Medicare or Medicaid). Moreover, private insurers lack meaningful and universal strategies to reduce RD cost burden, even at the level of orphan drugs that are prescribed to RD patients [27, 28]. In sum, there remains a significant opportunity to streamline RD clinical management and broaden effective treatments to reduce cost burden and improve patient outcomes.
How can the economic impact and system utilization of RDs be reduced through improved management?
Costs associated with a rare disease include frequent and multidisciplinary care expenses, costly procedures, and expensive medications [17, 29]. Diagnostic delays of RDs contribute to this financial burden . The majority of RD patients must leave their health-care system (e.g., out-of-network, out-of-geographical region) and visit at least 3–10 doctors prior over the course of years before receiving a definitive diagnosis and beginning treatment [17, 30]. These diagnostic inefficiencies not only result in the potential of leading to costly and unnecessary treatments [31, 32], but they also can push the patient beyond treatment windows, a major concern for life-shortening conditions. For example, delayed diagnosis has been reported to result in poorer outcomes and substantially increased cost for the rare conditions Krabbe disease and severe combined immunodeficiency [9, 33, 34]. This may also contribute to the high average cost ($89,539) and duration (9.1 days) of pediatric RD inpatient stays reported in the current study. Therefore, to provide the most effective therapies for RD patients, multiple approaches should be taken to address the issues of diagnostic delay and initiating best-in-class treatments for RD patients, such as improved clinician education, continued development of new drugs and gene therapies, and reduced time to diagnosis due to expanded newborn screening.
The overall cost of RDs is likely larger than the current HCUP utilization analysis. HCUP estimate charges likely underestimate the true costs of these conditions because they do not factor direct costs such as professional (e.g., physician, dentist, and other clinicians) fees, indirect costs (e.g., lost work productivity), and secondary downstream health-care effects.
HCUP databases are useful for giving estimates on a national scale. There are, however, several limitations of HCUP sample data: (1) the frequencies represent hospital discharges, and not patients, and thus, recurrent hospitalizations by the same patient appear as distinct observations; (2) the prevalence data may be affected by hospital coding; (3) databases do not capture outpatient encounters, and the full health-care utilization of patients suffering from RDs is underrepresented; (4) data do not represent the complete universe of all discharges in the United States since not all states participate; (5) hospital charges represent the bill that is sent to the payer, not the actual cost to the hospital which may vary, depending on reimbursement, if any; (6) the number of rare conditions included in this study primarily correspond to ICD-10 codes provided by Orphanet, which is far from the nearly 7,000–10,000 rare conditions currently described; (7) patients with undiagnosed rare conditions are not included in the RD cohort; (8) conditions are heterogeneous and genetic basis may affect only a disease subpopulation; (9) the ICD-10 codes used also include CC, which are unable to be separated from RDs, and thus are included in the health-care utilization and cost data reported here; and (10) we did not distinguish conditions in Table S3 that are indicated as having a genetic basis due to genetic susceptibility, genetic role in the phenotype, or disease-causing somatic mutation(s) from those with disease-causing germline mutation(s).
The cost of RDs needs to be calculated to better allocate resources and to find ways to ameliorate individual and societal costs. Resources should be allocated not according to the prevalence of a certain disease, but rather according to where intervention yields the most cost-efficient value. This study demonstrates that during the year 2016, the total national cost of RDs was disproportionate and considerably greater than CCs. Pediatric and adult populations with RDs had longer hospitalizations, more charges per admission, more readmissions, and more mortality than CC patients. Improvements in patient management and health-care utilization strategy may lead to substantial improvement to clinical care and decreased cost burden. Thus, expanded newborn screening tests, health-care-focused artificial intelligence, and other approaches to detect these conditions early in the disease course must be developed and incorporated into the clinical decision-making process to streamline patient care and reduce cost.
Data sets are available upon request to the corresponding author (S.R.G.) and can be shared after consulting our local institutional review board and the Agency for Healthcare Research and Quality.
Computer code used to generate data be accessed from the corresponding author.
Stoller JK. The challenge of rare diseases. Chest. 2018;153:1309–14.
Rodwell C, Ayme S. Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta. 2015;1852:2329–35.
Shah RR. Regulatory framework for the treatment of orphan diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford. 2006.
Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19:77–8.
Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–73.
EURODIS. Rare Diseases: understanding this Public Health Priority. 2005;1-27.
Herder M. What is the purpose of the orphan drug act? PLoS Med. 2017;14:e1002191.
Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18:906–14.
King S, Lehrman SN, Lehrman S. Newborn screening and early intervention for the treatment of rare diseases a Win-Win for children with rare diseases and North Carolina. 2018.
Grosse SD, Thompson JD, Ding Y, Glass M. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. The Milbank Q. 2016;94:366–91.
Murdock S, Lee JY, Guckes A, Wright JT. A costs analysis of dental treatment for ectodermal dysplasia. J Am Dent Assoc. 2005;136:1273–6.
Friedlander L, Berdal A, Boizeau P, Licht BA, Manière MC, Picard A, et al. Oral health related quality of life of children and adolescents affected by rare orofacial diseases: a questionnaire-based cohort study. Orphanet J Rare Dis. 2019;14:124.
López-Bastida J, Oliva-Moreno J. Cost of illness and economic evaluation in rare diseases. Adv Exp Med Biol. 2010;686:273–82.
Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong - adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis. 2018;13:147.
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015;119:964–79.
Michaels-Igbokwe C, McInnes B, MacDonald KV, Currie GR, Omar F, Shewchuk B, et al. (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada. Genet Med. 2021;23:272–9.
Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12:68.
Gonzaludo N, Belmont JW, Gainullin VG, Taft RJ. Estimating the burden and economic impact of pediatric genetic disease. Genet Med. 2019;21:1781–9.
http://www.orphadata.org/cgi-bin/index.php (2018). Accessed September 15, 2018.
Orphanet. Free datasets powered by Orphanet. In:2019.
https://omim.org (2021). Accessed March 26, 2021.
HCUP National Inpatient Sample (NIS). In: Rockville, MD, editor. Quality AfHRa. Agency for Healthcare Research and Quality. 2016.
HCUP Kids’ Inpatient Database (KID). In: Rockville, MD, editor. Quality AfHRa. Agency for Healthcare Research and Quality. 2016.
Barrett ML, Bailey MB. https://www.hcup-us.ahrq.gov/db/nation/nis/NISChangesforDataYear2016.pdf (2016). Accessed September 18, 2020.
Yoon F, Sheng M, Jiang HJ, Steiner CA, Barrett ML Calculating nationwide readmissions database (nrd) variances. US Agency for Healthcare Research and Quality. 2017.
HCUP Nationwide Emergency Department Sample (NEDS). In: Rockville, MD, editor. Quality AfHRa. Agency for Healthcare Research and Quality. 2016.
Robinson SW, Brantley K, Liow C, Teagarden JR. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans. J Manag Care Spec Pharm. 2014;20:997–1004.
Handfield R, Feldstein J. Insurance companies’ perspectives on the orphan drug pipeline. Am Health Drug Benefits. 2013;6:589–98.
Divino V, DeKoven M, Kleinrock M, Wade RL, Kaura S. Orphan drug expenditures in the United States: a historical and prospective analysis, 2007-18. Health Aff (Millwood). 2016;35:1588–94.
Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30.
Baynam G, Pachter N, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, et al. The rare and undiagnosed diseases diagnostic service - application of massively parallel sequencing in a state-wide clinical service. Orphanet J Rare Dis. 2016;11:77.
Gahl WA, Mulvihill JJ, Toro C, Markello TC, Wise AL, Ramoni RB, et al. The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine. Mol Genet Metab. 2016;117:393–400.
Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease.New Engl J Med. 2005;352:2069–81.
Allewelt H, Taskindoust M, Troy J, Page K, Wood S, Parikh S, et al. Long-term functional outcomes after hematopoietic stem cell transplant for early infantile Krabbe disease. Biol Blood Marrow Transplant. 2018;24:2233–8.
This research was supported by the Advocate Aurora Research Institute, Ed Howe Center for Health Care Transformation, Aurora Health Care Foundation, and David V. Uihlein Foundation. The authors thank Jillene Kogan, Laura McFarlane, and Jennifer Thomas for their input on the initial study approach. The authors also thank Christopher Blumberg for his assistance in data analysis. The opinions expressed in this article are the authors’ (A.T., C.M.C.) own and do not reflect the views of the National Institutes of Health.
This research was approved by the Advocate Aurora Health investigational review board.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Navarrete-Opazo, A.A., Singh, M., Tisdale, A. et al. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med 23, 2194–2201 (2021). https://doi.org/10.1038/s41436-021-01241-7
The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems
Orphanet Journal of Rare Diseases (2021)